Back to Peter Attia MD

395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more

Peter Attia MDJune 9, 20261h 44m
Topics51
Introduction to Brain Cholesterol and Lipids0:00Peripheral Cholesterol Synthesis and Transport0:30HDL and ApoA1 Particles3:00VLDL, IDL, and LDL Particles4:30LDL Clearance and HDL Function5:30Reverse Cholesterol Transport7:00Implications for LDL Lowering8:30Plasma as Transport Highway9:30Particle Numbers vs. Cholesterol Carrying Capacity11:00LDL Reduction and System Balance12:00Plasma vs. Total Body Cholesterol Stores13:30Brain Cholesterol Content15:30Misconceptions About Lowering Plasma Cholesterol17:00Atherosclerosis Pathophysiology18:00Plaque Formation Process20:30Surrogate Markers and Treatment Implications22:30Heterogeneity of Disease Expression23:30Brain Cholesterol Independence27:30Brain Cholesterol Independence from Peripheral Sources27:57Why the Brain Requires Abundant Cholesterol28:31Developmental Shifts in Brain Cholesterol Synthesis30:30Brain Lipid Transportation System33:01Neuronal Cholesterol Uptake Mechanisms36:30LDL Receptor Binding Mechanics37:30Receptor Specialization for APOE Particles41:32Cholesterol Synthesis Pathways in Brain vs Periphery43:30APOE Genotypes and Protein Isoforms48:00HDL Functionality Beyond Cholesterol Transport52:30Blood-Brain Barrier Crossing by Small HDL Particles55:32Brain HDL Particles and APOE Subtypes57:20APOE4 and Dysfunctional Brain HDL58:32Cholesterol, APP, and Amyloid Production59:02Cholesterol Overload in Alzheimer's Brains1:00:01Neuronal Cholesterol Elimination via 24S-Hydroxycholesterol1:03:0024S-Hydroxycholesterol as a Biomarker1:07:02APOE4 Effects on Neuronal Cholesterol Delivery1:08:31Statins and Brain Cholesterol Homeostasis1:09:31Desmosterol Monitoring During Statin Therapy1:17:32Statin Effects on 24S-Hydroxycholesterol1:19:00Ezetimibe and Potential Brain Effects1:20:01Omega-3 Fatty Acids in Brain Health1:24:01Absorption of Omega-3 Fatty Acids in the Intestine1:25:25Transport of Omega-3 Phospholipids in Plasma1:27:00Peripheral versus Brain Effects of EPA and DHA1:28:30Evidence Hierarchy for Omega-3 Index and Brain Health1:29:30Target Omega-3 Index Levels1:31:30CETP Inhibitors and Alzheimer’s Disease Biomarkers1:32:30Mechanism of CETP Inhibition on Brain HDL Particles1:34:30Future Research Directions for Obicetrapib1:36:30Importance of Trial Design and Timing1:37:30Closing Remarks on Brain Lipidology1:39:00
In a Nutshell

The brain produces and manages all its own cholesterol independently of plasma levels, using astrocytes to synthesize it and APOE-containing HDL-like particles to deliver it to neurons via the matriosome. APOE4 impairs this delivery, disrupts membrane cholesterol balance, and increases amyloid-beta 42 production, elevating Alzheimer's risk, while excess neuronal cholesterol is eliminated as 24S-hydroxycholesterol. Statins and CETP inhibitors can modulate brain cholesterol synthesis and enhance protective apoA1 transport across the blood-brain barrier, respectively, offering potential therapeutic avenues when monitored via desmosterol and oxysterol biomarkers.

AI-Generated Notes

These notes were generated by AI and may contain inaccuracies.

Peter Attia welcomes Tom Dayspring back to discuss cholesterol in the brain, noting this has become an enormous passion and area of curiosity. They begin with foundational knowledge about lipids to ensure everyone starts from the same baseline.

Cholesterol is essential for human life and is used for making critical molecules, but its most important function is positioning itself in cell membranes throughout the body. Cell membranes regulate integrity and control what enters and exits cells. Evolution has given every cell in the body the ability to de novo synthesize the cholesterol it needs. Each cell needs only a minor number of cholesterol molecules, but if a cell over-synthesizes or accumulates excess cholesterol, the cholesterol can crystallize, which is toxic to the cell and will kill it.

Evolution has given cells the ability to export excess cholesterol out of the cytosol into plasma. However, lipids are hydrophobic and cannot circulate freely in plasma, which is an aqueous solution. Evolution solved this by providing proteins that bind to lipids and wrap them into particles called lipoproteins, allowing lipids including cholesterol and triglycerides to circulate in the bloodstream.

When a cell fluxes cholesterol out, it joins with a protein called APOA1, the structural protein of high-density lipoproteins (HDLs). HDLs accept cholesterol from any cell in the body that is effluxing it. The apoB family of lipoproteins are much bigger than HDLs and are produced in the liver, with one type produced in the small intestine. The structural protein of apoB lipoproteins is the very large peptide called apolipoprotein B.

Sign in to read the full notes

Get access to AI-generated notes, topic timestamps, and more.